Floatz logo

Deucrictibant

Angioedema

Institute for Asthma and AllergySmall moleculePhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Angioedema cohort.

Asset / SponsorPhaseRating
Firazyr
Shire
Phase 3BB
Lanadelumab
D
HEPARIN
University of Iowa
N/AD
Recombinant Human C1 Inhibitor
Pharming Technologies B.V.
Phase 3NR

Same molecule, other indications

Deucrictibant is also rated in:

hereditary angioedema with C1Inh deficiencyDormant
BBB
Indicative ·
78 / 100
View asset →
C1 Esterase Inhibitor DeficiencyDormant
BBB
Indicative ·
78 / 100
View asset →
C1 Inhibitor DeficiencyDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →